{"name":"OcuTerra Therapeutics, Inc.","slug":"ocuterra-therapeutics-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxNZ3d4Zlc1dElVXzBYRk52cDNiSnFZbVJ0NGRpdVN3dnJSeGpGVGtldEFiTWdESUxIcFctaTljanY2elFrbWtUamRpYWotQ0xFMGNHRWxzWnpWTUFjemx4Vmd6TzhZMnJsTWJVbzUycFVwcU5UVlAtRzhyVXNEc3RHYWFnaUhRWnUtTGFoOE5vdjg5Rm4tYkFnbjJjUENJdGFfcjVBelotUkFDZw?oc=5","date":"2024-03-20","type":"trial","source":"Eyes On Eyecare","summary":"OcuTerra fails endpoints in phase 2 DR eye drop study - Eyes On Eyecare","headline":"OcuTerra fails endpoints in phase 2 DR eye drop study","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxQeGRQbHZRYndKLVdZUFd1Y2ZBWGhKeDVXOVJyN0VYOWtOX3RkVXd4RGw3NUFxTE9MV0Z1ZGhnTTV1X0piZFhHMlhpUVpveEpZREJSNGdjUUI4TWNKeElqeGZMdER3MGV2T2tOVV9zVk1TUmwxbTVSeUcyVHJnUVlKVGJVSGFBZ2F0SmNQOGJBb2hUZ1dY?oc=5","date":"2024-03-14","type":"trial","source":"Fierce Biotech","summary":"Phase 2 fail sends OcuTerra's eye drop dreams down the drain - Fierce Biotech","headline":"Phase 2 fail sends OcuTerra's eye drop dreams down the drain","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMikwJBVV95cUxQYkNiLXpHZWJKcUFnaXJOQ295aW5JUnJ0WjdlSTJ1cm8zVTdkNDFmbEtLd2pGYlE2VkpCck5idjVwNTRDbzlDY3lhU2FFazJSWndVZ256OURwNDE3REphUDNUSjIzRVJ5MlpDRkw0MVZTanh0UEx1LTYxRTNmUEl1dkZSUEpxdEtDMk9wZTJZeWtyeUpnMmY4Z0ZEQVQwXzNtV1dNXzQ0LWVoQmNBWjdiVnRUTUhOY3JKSldVdkJyQkdlNEVYb2RZdVUxQThZWF9mSXo0a25EUGYzZUlqS2lRanU1YTNUdGw0YVVMYnZpU3VabW5VOFVDNHVxcjVXaGQ5amdIbmhySmZtT3JuTHpUOWRnQQ?oc=5","date":"2024-03-14","type":"trial","source":"businesswire.com","summary":"OcuTerra Announces Topline Data from Phase 2 DR:EAM Trial Evaluating Nesvategrast (OTT166 5%) for Patients with Diabetic Retinopathy - businesswire.com","headline":"OcuTerra Announces Topline Data from Phase 2 DR:EAM Trial Evaluating Nesvategrast (OTT166 5%) for Patients with Diabetic","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixgFBVV95cUxOSGFNVG52NnVzeXNQbUJXUmJtLUZaSy1RQ19IbkhpNkY0aWtGNkpYT1FESTRNMWh5T1A0QWxIck1fQURpc1E3T3Y2MkY1eGI5YkRFcGltSEc5endxVnIxQnVpeFhvX2VuRHdpLUtFZzBLbzAzLWg5bkRiazY5LUVKdDMtdGJnaG1xZWxDZXFSLTIwMVpUZlp1QTNHM0dVSnZ3YkxBRnJrOFFhLWNBODRIbzU5ZFdlNWV2QkdoS0RwR2JtdlQ4dlE?oc=5","date":"2024-02-09","type":"pipeline","source":"Healio","summary":"APX3330 ‘promising’ oral treatment option for slowing progression of diabetic retinopathy - Healio","headline":"APX3330 ‘promising’ oral treatment option for slowing progression of diabetic retinopathy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxOS1ZPQUVnMGo3SXdzdWJWb0NkZ1QxUHdKOHp1WjdpakEyMmd2Szh2X2FUM3BwQ0s0T0ZWQ1NZYTRmUHNfQm1mTkF4UTdBd204ZEVpSVdQaFNYSktBX3hvbjgxdHVoanp4OU4zcEVDN1ZKaFBmdFBoRlBLODZnSXZ1QTlEMXdqTnh3ZnRfRG1yT0pQVzA?oc=5","date":"2024-01-12","type":"pipeline","source":"Fortune Business Insights","summary":"U.S. Ophthalmic Disease Therapeutics Market Size, Share, 2030 - Fortune Business Insights","headline":"U.S. Ophthalmic Disease Therapeutics Market Size, Share, 2030","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE83OWFoQVJNcjhrcjZfQllVTl9XUzlwQml0ZEFoUlNGcGZhNVlaTjRfLWpBVDZ1cEs2RzJROWNDVEw5NmU1T0ZJYjhrSGp0SjhWbG5DWlpVR1I2VVhodmlv?oc=5","date":"2023-10-26","type":"earnings","source":"Nature","summary":"Prediction of activity in eyes with macular neovascularization due to age-related macular degeneration using deep learning - Nature","headline":"Prediction of activity in eyes with macular neovascularization due to age-related macular degeneration using deep learni","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgJBVV95cUxOckQ5OEkzUVMyRDA4a0FVaUdHeXgzd3dkSzhmVjR3dlRabU9PQzI4MkpVMzY5czRoU1JXdU1maklPdTI1Zi1nR1NTbG5jZWhwdDhBa1ZEbHpfdFYyODV4N244YUlrU3JRd3lsNmtOMEVudVpnUWpyeVYxdExyV2RsSVNhV01HdUhEc19Nc0JOa1g1c2tISVhnakloQUZQNTh0Vlk1Y3FXV01pc1E4OUx5aUducVFVcnJob3VuSG9ZNlhJeGdTUnlUV1RHYk05TVJ4NDRUYm9aYVY4dUM2Uy1JU2JzRlJqcEluVnVKYm84OXRVczE4aFo3RzR1YUt1YXdjY2NCLURYd1dZc1JUNGw1TDNn?oc=5","date":"2023-07-18","type":"trial","source":"businesswire.com","summary":"OcuTerra Completes Enrollment in Phase 2 DR:EAM Clinical Trial of Topically Delivered OTT166 in Adults with Diabetic Retinopathy - businesswire.com","headline":"OcuTerra Completes Enrollment in Phase 2 DR:EAM Clinical Trial of Topically Delivered OTT166 in Adults with Diabetic Ret","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixgFBVV95cUxNbXJrc0F2N3NBcjRHSGFmTDI5LXFYX2NyWkNmZWRadTBJY0pGMG10dXhvQ3lNUGlFVlJCVDhCUXAyVENqZ1BZZEktZDB2RjRwT1ZuOVRjLXFkb0JiN0s2bWJ1dWh6VFRGSnh3UnB3bkVLaDNaMnA3eWpXOGtEN00ySGYwemFuRkVPYXFFVGZaRXBjSE5VZWlXSHpMTVVGcnd2b003TTUxOTdxVDF2dTE5ZnBVY1RUenhYR05Qc0FqaGYyR3ZtTXc?oc=5","date":"2022-04-08","type":"pipeline","source":"Fierce Biotech","summary":"Chutes & Ladders—Fierce Biotech launches Layoff Tracker amid dizzying number of industry job cuts - Fierce Biotech","headline":"Chutes & Ladders—Fierce Biotech launches Layoff Tracker amid dizzying number of industry job cuts","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxOR2E4ZHBvNm92ZktVUFlma2J3Qm1QN3FmSGFhMnlWZzNlSEhTTHNHVWNTWWgzcUF1SmdzY2J4b1RmeWdldHFoN3pmN0VKY1VrVnVLcXBPMmtLN2ZRZjlaVDc0OTdOMHgzb21uQnl5NVB0Mk12STJsM1YyaV9WMHllYnIyVmpja1JCR2hxRUdqcWRRdzFrd1VBZGQxc3djZTl4cmVucDlSVTduWjhENHJCWGRn?oc=5","date":"2021-11-09","type":"trial","source":"Fierce Biotech","summary":"OcuTerra snags $35M for phase 2 trial of eye drop with former Allergan CEO as chair - Fierce Biotech","headline":"OcuTerra snags $35M for phase 2 trial of eye drop with former Allergan CEO as chair","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}